Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

4.11
-0.0300-0.72%
Post-market: 4.110.00000.00%16:05 EDT
Volume:1.10M
Turnover:4.65M
Market Cap:304.98M
PE:-1.80
High:4.75
Open:4.57
Low:4.10
Close:4.14
Loading ...

Olema Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Olema Pharmaceuticals Q3 EPS $(0.60) Misses $(0.57) Estimate

Benzinga
·
13 Nov 2024

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
13 Nov 2024

Olema Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire
·
06 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Nov 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Nov 2024

Promising Potential of Olema Pharmaceuticals’ Palazestrant and KAT6 Inhibitor Fuels Buy Rating

TIPRANKS
·
24 Oct 2024

Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Oct 2024

Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy

TIPRANKS
·
24 Oct 2024

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

GlobeNewswire
·
23 Oct 2024

Olema Oncology to present multiple posters at EORTC-NCI-AACR

TIPRANKS
·
09 Oct 2024

Olema Oncology Announces New Preclinical Combination Data to Be Presented at the 2024 Eortc-Nci-Aacr Symposium on Molecular Targets and Cancer Therapeutics

THOMSON REUTERS
·
09 Oct 2024

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire
·
09 Oct 2024